Inhibition of factor Xa-mediated procoagulant activity of human lung fibroblasts and pleural mesothelial cells

被引:3
作者
Kumar, A
Koenig, KB
Johnson, AR
Fair, DS
Idell, S
机构
[1] UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,TYLER,TX 75710
[2] UNIV TEXAS,HLTH SCI CTR,DEPT MED,TYLER,TX 75710
关键词
coagulation; fibrin deposition; human lung fibroblasts; pleural mesothelial cells; monoclonal antibody; pleural diseases; prothrombinase complex;
D O I
10.1183/09031936.95.08122038
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Extravascular fibrin deposition characterizes diverse forms of lung and pleural injury. Fibrin formation in these compartments is locally potentiated by the assembly and expression of the prothrombinase procoagulant complex (factors Xa, Va and II) at the surface of human lung fibroblasts and pleural mesothelial cells. We sought to identify structural domains on factor Xa that mediate expression of prothrombinase activity by these cells. In order to accomplish this objective, we used panels of monoclonal antibodies (MoAbs) to factor X to block prothrombinase assembly and function on the surface of cultured human lung fibroblasts and pleural mesothelial cells. Of 30 factor X MoAbs that recognized native factors X and Xa, 10 completely inhibited factor Xa function (prothrombin activation), and five others neutralized Xa function without affecting cell-binding, presumably by blocking the prothrombin binding site. Western blots showed that these inhibitory MoAbs reacted with the Xa heavy-chain. One MoAb that recognized the factor Xa light-chain blocked prothrombin activation at the factor Va binding site. Our results indicate that prothrombinase activity at the surface of lung parachymal or pleural cells can be blocked by MoAbs that interact with either the heavy- or light-chain of factors X. Antibodies that neutralize cell surface-expressed prothrombin activation offer a potential means to arrest pericellular fibrin formation in the lung and pleural space.
引用
收藏
页码:2038 / 2045
页数:8
相关论文
共 34 条
[1]  
ALTEIERI AC, 1988, P NATL ACAD SCI USA, V85, P7462
[2]  
BROWN LF, 1989, AM REV RESPIR DISD, V140, P104
[3]   REGULATION OF THE PROCOAGULANT ACTIVITY WITHIN THE BRONCHOALVEOLAR COMPARTMENT OF NORMAL HUMAN-LUNG [J].
CHAPMAN, HA ;
STAHL, M ;
ALLEN, CL ;
YEE, R ;
FAIR, DS .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 137 (06) :1417-1425
[4]  
CHATTOPADHYAY A, 1989, J BIOL CHEM, V264, P11035
[5]  
CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323
[6]   HUMAN COAGULATION FACTOR-V PURIFICATION AND THROMBIN-CATALYZED ACTIVATION [J].
DAHLBACK, B .
JOURNAL OF CLINICAL INVESTIGATION, 1980, 66 (03) :583-591
[7]  
DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
[8]   COMBINED FUNCTIONAL AND IMMUNOCHEMICAL ANALYSIS OF NORMAL AND ABNORMAL HUMAN FACTOR-X [J].
FAIR, DS ;
PLOW, EF ;
EDGINGTON, TS .
JOURNAL OF CLINICAL INVESTIGATION, 1979, 64 (04) :884-894
[9]  
FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0
[10]   FUNCTIONAL-SIGNIFICANCE OF THE KUNITZ-TYPE INHIBITORY DOMAINS OF LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR [J].
GIRARD, TJ ;
WARREN, LA ;
NOVOTNY, WF ;
LIKERT, KM ;
BROWN, SG ;
MILETICH, JP ;
BROZE, GJ .
NATURE, 1989, 338 (6215) :518-520